SecBot SecBot

NGEN drug pipeline

NERVGEN PHARMA CORP. · 1 rated drug
$1.82
−3.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3 (registrational)
Time to marketIf Phase 3 RESTORE succeeds, a potential FDA submission could occur in 2028-2029, assuming enrollment completes and the 16-week treatment period yields positive results. Breakthrough Therapy designation may accelerate FDA review.

NVG-291 Updated Nov 13

What to watch

The next major catalyst is the Phase 3 RESTORE topline data readout, likely in late 2027 or 2028 given enrollment just began in October 2026. Positive data would validate NVG-291 as a first-in-class neuroreparative therapy for a large unmet need with no approved pharmacologic alternatives; negative data would be devastating for this single-asset company. Interim enrollment updates or any early efficacy signals could also move the stock.

Bull case
  • FDA granted Breakthrough Therapy designation on November 12, 2026, based on positive Phase 1b/2a chronic cohort data, which can expedite development and expedited review.
  • Positive topline data from the Phase 1b/2a CONNECT SCI study showed functional hand use improvements in chronic spinal cord injury patients, with no serious adverse events or treatment discontinuations.
  • Successful End-of-Phase 2 meeting with FDA alignment on the Phase 3 RESTORE study design, including agreement on the primary endpoint (GRASSP Quantitative Prehension at Week 12).
Bear case
  • Phase 3 RESTORE study just began dosing (October 2026); enrollment and topline data are likely 12-18+ months away, creating a long binary wait with no near-term catalyst.
  • The company is a single-asset developer (NVG-291 is its only pipeline drug), making the stock extremely sensitive to any negative development.
  • NervGen raised US$60M in a dilutive May 2026 offering priced at $2.50/share, and the stock has fallen roughly 62% year-to-date before the recent Breakthrough Therapy bounce.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
NVG-291NVG-291 in Spinal Cord Injury SubjectsPhase 2Completed24Dec 31, 2025